Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP501 + Cisplatin + Nivolumab in Advanced Refractory Tumors
NCT03113188Phase 1Completed
- Sponsor
- CanBas
- Start
- Oct 2017
- Primary completion
- Feb 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBP-501 in solid tumor (advanced stage), pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by CanBas. Primary endpoint: Recommended dose at 21 days. Started Oct 2017; status: completed.
02
Drugs
CBP-501
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03113188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113188.